iQ&A Interactive Medical Intelligence Zone for GEP-NETs Recent Advances
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor..

The iQ&A platform stresses:

  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period December 11, 2015 through December 11, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 87 segments, totaling 3 hours and 30 minutes, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

3.5 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of gastrointestinal and neuroendocrine tumors.

Release Date

December 11, 2015

Expiration Date

December 11, 2017

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with or at risk for metastatic gastrointestinal and pancreatic neuroendocrine tumors.

This constituency of HCPs shall include the following audience: GI oncologists, general clinical oncologists, neuroendocrine tumor specialists, gastroenterologists, GI cancer specialists, general surgical and GI surgical oncologists, oncology nurses and nurse practitioners, and related healthcare providers who manage GI cancers.


Participation in this iQ&A interactive Medical Intelligence Zone for Comprehensive Thrombosis Care is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals. 

Grantor Support

This activity is supported by an independent medical education grant from Ipsen..

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials. 

Program Faculty and Disclosure

Johanna Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Nothing to disclose

Professor of Medicine
Associate Director for Clinical Investigations
Robert H. Lurie Comprehensive Cancer Center
of Northwestern University
Chicago IL

Consultant/Advisory Board: Alchemia, Bayer, Celgene, Eli Lilly/Imclone, Genentech, Genomic Health, Gilead, Infinity, Merck, Pharmacyclics, Sanofi, Taiho, and Targovax. Grant/Research Support: Advanced Accelerator Applications, Amgen, Astellas/Aveo, Bayer, Genentech, Gilead, and Novartis.

Emily Bergsland, MD
Professor of Clinical Medicine
Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Grant/Research Support: Lexicon, Novartis

Michael A Choti, MD MBA FACS
Professor and Chair
Department of Surgery
UT Southwestern Medical Center
Dallas, TX

Nothing to disclose

Mauro Cives, MD
Department of GI Oncology
H. Lee Moffitt Cancer Center and Research Institute,
Tampa, Florida

Nothing to disclose

Professor Andrea Frilling, MD, PhD, FACS, FRCS, FEBS
Professor of Surgery
Chair in Endocrine Surgery
Consultant Surgeon
Department of Surgery and Cancer
Imperial College London
London, United Kingdom

Speakers Bureau: Novartis, Ipsen

Renuka Iyer, MD
Roswell Park Cancer Institute
Associate Professor of Oncology
Co-Director, Liver and Pancreas Tumor Center
Section Chief for Gastrointestinal Oncology
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Assistant Professor of Medicine
Buffalo, NY

Nothing to disclose

Pamela L.Kunz, MD
Assistant Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford, CA

Nothing to disclose

Diane Reidy-Lagunes, MD
Medical Oncologist
Co-Director, Department of Medicine’s Hematology-Oncology Fellowship Program
Memorial Sloan Kettering Cancer Center
New York, NY

Advisory Board: Novartis, Pfizer, Ipsen
Grant/Research Support: Novartis

Michael Morse, MD
Professor of Medicine
Division of Oncology
Duke University School of Medicine
Durham, NC

Consultant: Ipsen
Speaker’s Bureau: Novartis, Genentech, Onyx, Bayer, Sanofi
Grant/Research Support: Eisai

Alexandria Phan, MD
Associate Professor
Houston Methodist Cancer Center
Director, GI Medical Oncology
Houston, Texas

Speaker’s Bureau: Celgene Corporation; Novartis
Grant/Research Support: GlaxoSmithKline; Ipsen; Novartis

Philip Agop Philip, MD, PhD, FRCP
Professor of Oncology and Medicine
Vice President of Medical Affairs
Leader, GI & Neuroendocrine Tumor Multidisciplinary Team
Karmanos Cancer Center
Wayne State University School of Medicine
Detroit, MI

Consultant: Ipsen, Novartis

Jonathan R. Strosberg, MD
Section Head, Neuroendocrine Division
Chair, Gastrointestinal Department Research Program
Moffitt Cancer Center and Research Institute
Assistant Professor
Department of Oncologic Sciences
University of South Florida College of Medicine
Tampa, FL

Consultant: Novartis, Ipsen
Speakers Bureau: Pfizer
Grant/Research Support:Novartis

Yi-Zarn Wang DDS, PC, MD, FACS
Professor of Surgery
Division of Surgical Oncology
Department of Surgery
LSUHSC-New Orleans
New Orleans, LA

Nothing to disclose

Edward M. Wolin, MD
Professor of Medicine
Director, Neuroendocrine and GI Oncology Program
Director of Clinical Research
Markey Cancer Center
University of Kentucky
Lexington, KY

Consultant: Ipsen, Novartis, Celgene

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Detail the epidemiology, burden, and clinical challenges associated with detecting, diagnosing and classifying gastroenteropancreatic neuroendocrine tumors (GEP-NETs);
  • Be more clinically proficient at managing metastatic GEP-NETs at the front lines of oncology practice;
  • Determine which patients with metastatic GEP-NET are appropriate for surgical interventions (resection), medical therapy, systemic chemotherapy, and peptide receptor-targeted radiotherapy, based on presentation, symptoms, tumor types and stage, clinical profiles, extent of disease, biomarkers, and other factors;
  • Identify, assess, and deploy evidence-based treatments for metastatic GEP-NETs based on such outcomes and factors a prolongation of PFS, convenience, patient toleration, and long-term clinical results based on landmark trials and clinical registries;
  • Deploy emerging pharmacologic treatments for patients with GEP-NETs, including somatostatin analogs (SSAs), radiolabeled SSAs, cytotoxic drugs, angiogenesis inhibitors, and mammalian target of rapamycin (mTOR) inhibitors in patients with metastatic GEP-NETs

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2015 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC